Allogeneic stem cell transplantation in MDS: How? When?

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 4, 2013, Pages 421-429

  Platzbecker, Uwe ^a   Mufti, Ghulam ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

allogeneic hematopoietic stem cell transplantation; hypomethylating agents

Indexed keywords

AZACITIDINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; DISEASE CONTROL; GRAFT VERSUS HOST REACTION; HUMAN; LONG TERM CARE; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; QUALITY OF LIFE; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; REVIEW;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; HYPOMETHYLATING AGENTS;

ALLOGRAFTS; HUMANS; MYELODYSPLASTIC SYNDROMES; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING;

EID: 84893730210     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2013.09.008     Document Type: Review

References (63)

1. P. Greenberg, C. Cox, and M.M. LeBeau et al. International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079 2088
2. C.S. Cutler, S.J. Lee, and P. Greenberg et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome Blood 104 2004 579 585
3. P. Fenaux, G.J. Mufti, and V. Santini et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study Blood 110 2007 250A 251A
4. U. Platzbecker, J. Schetelig, and J. Finke et al. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine Biol Blood Marrow Transplant 18 2012 1415 1421
5. J. Koreth, J. Pidala, and W.S. Perez et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis J Clin Oncol 31 2013 2662 2670
6. H.J. Deeg Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS) Hematol Am Soc Hematol Educ Program 2005 167 173
7. E.P. Alessandrino, M.G. Della Porta, and A. Bacigalupo et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) Blood 112 2008 895 902
8. B.L. McClune, D.J. Weisdorf, and T.L. Pedersen et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome J Clin Oncol 28 2010 1878 1887
9. P. Armand, H.T. Kim, and D.J. DeAngelo et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation Biol Blood Marrow Transplant 13 2007 655 664
10. J. Schanz, H. Tüchler, and F. Solé et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge J Clin Oncol 30 2012 820 829
11. B.L. Scott, D.A. Wells, and M.R. Loken et al. Validation of a flow cytometric scoring system as a prognostic indicator for post-transplant outcome in patients with MDS Blood 112 2008 2681 2686
12. P. Fenaux, G.J. Mufti, and E. Hellstrom-Lindberg et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 2009 223 232
13. M. Lubbert, H. Bertz, and B.H. Ruter et al. Non-intensive AML/MDS treatment with low-dose decitabine prior to reduced-intensity conditioning (RIC) and allogeneic blood stem cell transplantation of older patients Blood 108 2006 406B
14. T. Field, J. Perkins, and Y. Huang et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation Bone Marrow Transplant 45 2010 255 260
15. U. Platzbecker, M. Bornhauser, and U. Germing et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS) Biol Blood Marrow Transplant 14 2008 1217 1225
16. R. Bejar, K. Stevenson, and O. Abdel-Wahab et al. Clinical effect of point mutations in myelodysplastic syndromes N Engl J Med 364 2011 2496 2506
17. Z. Lim, R. Brand, and R. Martino et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia J Clin Oncol 28 2010 405 411
18. M.L. Sorror, M.B. Maris, and R. Storb et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT Blood 106 2005 2912 2919
19. M.L. Sorror Comorbidities and outcomes: advancing the field comes at a price Biol Blood Marrow Transplant 17 2011 1721 1723
20. B. Deschler, U. Platzbecker, and G. Ihorst et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome Haematologica 98 2013 208 216
21. T. de Witte, S. Suciu, and G. Verhoef et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS Blood 98 2001 2326 2331
22. H. Castro-Malaspina, A.A. Jabubowski, and E.B. Papadopoulos et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings Biol Blood Marrow Transplant 14 2008 458 468
23. B.L. Scott, B. Storer, and M.R. Loken et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome Biol Blood Marrow Transplant 11 2005 65 73
24. A.T. Gerds, T.A. Gooley, and E.H. Estey et al. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS Biol Blood Marrow Transplant 18 2012 1211 1218
25. G. Damaj, A. Duhamel, and M. Robin et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies J Clin Oncol 30 2012 4533 4540
26. U. Platzbecker, C. Thiede, and M. Fuessel et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia Leukemia 20 2006 707 714
27. C. Schmid, M. Schleuning, and G. Ledderose et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome J Clin Oncol 23 2005 5675 5687
28. R. Itzykson, S. Thepot, and B. Quesnel et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine Blood 117 2011 403 411
29. U. Platzbecker, M. Von Bonin, and E. Goekkurt et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial Biol Blood Marrow Transplant 15 2009 101 108
30. A.J. Barrett, and B.N. Savani Allogeneic stem cell transplantation for myelodysplastic syndrome Semin Hematol 45 2008 49 59
31. G. Mufti, and V. Potter Myelodysplastic syndromes: who and when in the course of disease to transplant Hematol Am Soc Hematol Educ Program 2012 2012 49 55
32. U. Platzbecker, L.C. Hofbauer, and G. Ehninger et al. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes Leuk Res 36 2012 525 536
33. P. Armand, M.M. Sainvil, and H.T. Kim et al. Does iron overload really matter in stem cell transplantation? Am J Hematol 87 2012 569 572
34. M. Wermke, A. Schmidt, and M. Middeke et al. Liver iron content - as determined by magnetic resonance imaging - is an independent predictor for early non-relapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation Bone Marrow Transplant 47 2012 S28 S29
35. H.K. Al Ali, N. Jaekel, and A. Nass et al. The oral iron chelator deferasirox for treatment of transfusional iron overload after allogeneic hematopoietic cell transplantation does not appear to interfere with the calcineurin inhibitor cyclosporin trough serum levels Blood 116 2010 762
36. K. Sockel, M. Bornhaeuser, and E. Mischak-Weissinger et al. Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial Haematologica 97 2012 E34 E35
37. H.J. Deeg, B.L. Scott, and M. Fang et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS Blood 120 2012 1398 1408
38. P.L. Greenberg, H. Tuechler, and J. Schanz et al. Revised international prognostic scoring system for myelodysplastic syndromes Blood 120 2012 2454 2465
39. J. Schanz, H. Tuchler, and F. Sole et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge J Clin Oncol 30 2012 820 829
40. U. Platzbecker, M. Binder, and C. Schmid et al. Second donation of hematopoietic stem cells from unrelated donors for patients with relapse or graft failure after allogeneic transplantation Haematologica 93 2008 1276 1278
41. P.V. Campregher, T. Gooley, and B.L. Scott et al. Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation Bone Marrow Transplant 40 2007 965 971
42. D.L. Porter, and J.H. Antin Donor leukocyte infusions in myeloid malignancies: new strategies Best Pract Res Clin Haematol 19 2006 737 755
43. C. Schmid, M. Labopin, and A. Nagler et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party J Clin Oncol 25 2007 4938 4945
44. R. Guieze, A. Jouinot, and R. Itzykson et al. Azacytidine (AZA) in relapsed MDS and AML after allogeneic stem cell transplantation (allo-HSCT): results of the French ATU Program Blood 116 2010 553 554
45. A. Czibere, I. Bruns, and N. Kroger et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis Bone Marrow Transplant 45 2010 872 876
46. O. Goodyear, A. Agathanggelou, and I. Novitzky-Basso et al. Induction of a CD8(+) T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia Blood 116 2010 1908 1918
47. M. Lubbert, H. Bertz, and R. Wasch et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting Bone Marrow Transplant 45 2010 627 632
48. ®, Aza) and donor lymphocyte infusions (DLI) As first salvage therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) relapsing after allogeneic hematopoietic stem cell transplantation (allo-SCT): final results from the AZARELA-trial (NCT-00795548) Blood 118 2011 300
49. M. de Lima, S. Giralt, and P.F. Thall et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome Cancer 116 2010 5420 5431
50. P. Fenaux, A. Giagounidis, and D. Selleslag et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q Blood 118 2011 3765 3776
51. D.H. Chang, N. Liu, and V. Klimek et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications Blood 108 2006 618 621
52. E. Kneppers, B. van der Holt, and M.J. Kersten et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial Blood 118 2011 2413 2419
53. M. Bornhauser, U. Elschlaegel, and U. Platzbecker et al. Monitoring of donor chimerism in sorted CD34(+) peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation Haematologica 94 2009 1613 1617
54. E.M. Sloand, J.J. Melenhorst, and Z.C.G. Tucker et al. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy Blood 117 2011 2691 2699
55. U. Platzbecker, M. Wermke, and J. Radke et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial Leukemia 26 2012 381 389
56. U. Platzbecker, and H.J. Deeg Graft-versus-host disease R.J. Soiffer, Hemopoietic stem cell transplantation 2004 The Humana Press Inc. 159 184
57. C. Cutler, S.L. Li, and V.T. Ho et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation Blood 109 2007 3108 3114
58. U. Platzbecker, and M. Bornhauser SOS for veno-occlusive disease: defibrotide prophylaxis Lancet 379 2012 1277 1278
59. C. Anasetti, B.R. Logan, and S.J. Lee et al. Peripheral-blood stem cells versus bone marrow from unrelated donors N Engl J Med 367 2012 1487 1496
60. G. Socie, C. Schmoor, and W.A. Bethge et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius Blood 117 2011 6375 6382
61. J.E. Parker, T. Shafi, and A. Pagliuca et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens Br J Haematol 119 2002 144 154
62. L. Luznik, R.J. Jones, and E.J. Fuchs High-dose cyclophosphamide for graft-versus-host disease prevention Curr Opin Hematol 17 2010 493 499
63. M. Wermke, A. Schmidt, and J.M. Middeke et al. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation Clin Cancer Res 18 2012 6460 6468